Tech Company Financing Transactions
ReCode Therapeutics Funding Round
ReCode Therapeutics, based in Menlo Park, secured $29 million from private investors.
Transaction Overview
Company Name
Announced On
9/29/2025
Transaction Type
Venture Equity
Amount
$29,000,000
Round
Undisclosed
Investors
Proceeds Purpose
It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1455 Adams Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Lockhart
Browse more venture capital transactions:
Prev: 9/29/2025: Solsten venture capital transaction
Next: 9/29/2025: RDS venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs